- Insider Monkey•3 days agoJapan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics Inc. (PSTI) Are Benefiting
Japan is the stem cell capital of the world. From the Nobel winning efforts of Shinya Yamanaka in the field of mature to pluripotent stem cell reprogramming, to the STAP scandal and its suicide tarnished fallout, if there’s something to talk about in the sector, chances are it happened first in Japan. Japan’s development of […]
- Capital Cube•5 days ago
Click here to see latest analysisCapitalcube gives Pluristem Therapeutics, Inc. a score of 28.Our analysis is based on comparing Pluristem Therapeutics, Inc. with the following peers – Vericel Corporation, Osiris Therapeutics, Inc., Athersys, Inc., Immunomedics, Inc., Cleveland BioLabs, Inc., Celgene Corporation, United Therapeutics Corporation, Caladrius Biosciences, Inc., Shenzhen Expressway Co., Ltd. Unsponsored ADR Class H […] (Read more...) The post Pluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : July 19, 2016 appeared first on CapitalCube.
|Bid||1.52 x 1100|
|Ask||1.53 x 500|
|52wk Range||0.71 - 2.45|
|Day's Range||1.51 - 1.53|
|Avg Vol (3m)||129,396|
As of 4:00 PM EDT. Market closed.